Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00130429
Recruitment Status : Completed
First Posted : August 15, 2005
Last Update Posted : August 21, 2009
Information provided by:

Brief Summary:
The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: PYM50028 Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type
Study Start Date : January 2004
Actual Study Completion Date : September 2005

Primary Outcome Measures :
  1. Hopkins verbal learning test (revised) total word recall after 12 weeks
  2. Cambridge neuropsychological test automated battery (CANTAB) paired associate learning (Phytopharm modified form) total adjusted error score after 12 weeks

Secondary Outcome Measures :
  1. Mini mental state examination score
  2. Clinical dementia rating (overall and sum of boxes)
  3. CANTAB rapid visual information processing (RVIP) mean latency
  4. CANTAB RVIP total correct hits
  5. CANTAB spatial working memory within error, between error and strategy scores
  6. Clinicians global impression of change
  7. Disability assessment for dementia score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 50 years of age
  • Diagnosis of possible or probable Alzheimer's disease
  • Mini mental state examination score at least 16
  • Good understanding of both written and verbal English
  • A recent head scan that is consistent with the diagnosis of Alzheimer's disease

Exclusion Criteria:

  • Recent history or clinical evidence of significant neurological disease other than dementia due to Alzheimer's disease
  • Known to have another condition that is associated with dementia
  • Use of psychotropic medication within the previous 4 weeks (excluding cholinesterase inhibitors, selective serotonin reuptake inhibitors and venlafaxine)
  • Hormone replacement therapy started or changed within the previous 6 months
  • Received any investigational drugs within the previous 12 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00130429

United Kingdom
Oxford Project to Investigate Memory and Ageing
Oxford, Oxfordshire, United Kingdom, OX3 7JX
Sponsors and Collaborators
Principal Investigator: Robin Jacoby, FRCPsych University of Oxford, UK Identifier: NCT00130429     History of Changes
Other Study ID Numbers: P58/09ME/03/04
First Posted: August 15, 2005    Key Record Dates
Last Update Posted: August 21, 2009
Last Verified: August 2009

Keywords provided by Phytopharm:
Hopkins verbal learning test
paired associated learning

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders